Skip to main content

Theravance Biopharma, Inc. (TBPH)

NASDAQ: TBPH · IEX Real-Time Price · USD
7.82 0.10 (1.30%)
Oct 25, 2021 4:00 PM EDT - Market closed
Market Cap574.54M
Revenue (ttm)64.16M
Net Income (ttm)-264.16M
Shares Out73.47M
EPS (ttm)-4.11
PE Ration/a
Forward PE9.53
Dividendn/a
Ex-Dividend Daten/a
Volume391,045
Open7.65
Previous Close7.72
Day's Range7.65 - 7.96
52-Week Range6.10 - 22.74
Beta0.88
AnalystsBuy
Price Target9.38 (+19.9%)
Est. Earnings DateNov 3, 2021

About TBPH

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative coliti...

IndustryPharmaceuticals
CEORick Winningham
Employees359
Stock ExchangeNASDAQ
Ticker SymbolTBPH
Full Company Profile

Financial Performance

In 2020, TBPH's revenue was $71.86 million, a decrease of -2.12% compared to the previous year's $73.41 million. Losses were -$278.02 million, 17.6% more than in 2019.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TBPH stock is "Buy." The 12-month stock price forecast is 9.38, which is an increase of 19.95% from the latest price.

Price Target
$9.38
(19.95% upside)
Analyst Consensus: Buy

News

Theravance Biopharma to Report Third Quarter 2021 Financial Results November 3, 2021

DUBLIN, Oct. 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), will report its third quarter 2021 financial results and provide a business update after market close on Wednesday, Novem...

5 days ago - PRNewsWire

Down 51.5% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analys...

1 month ago - Zacks Investment Research

Theravance (TBPH) to Cut Workforce, Hypotension Study Fails

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic neurogenic orthostatic hypotension fails to meet goal. The company plans to cut its workforce by 75%.

1 month ago - Zacks Investment Research

Why Theravance Biopharma Stock Dived 16% Today

The biotech is not enjoying a winning streak with its pipeline drugs.

1 month ago - The Motley Fool

Why Are Theravance Bio Shares Plummeting Premarket Today?

Theravance Biopharma Inc (NASDAQ: TBPH) will reduce its headcount by approximately 75% (estimated 270 positions), with most of the lay off to complete in November and the remainder in February 2022. The...

1 month ago - Benzinga

Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio

DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced strategic actions to focus on l...

1 month ago - PRNewsWire

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptoma...

DUBLIN and SOUTH SAN FRANCISCO, Calif., Sept, 15, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primar...

1 month ago - PRNewsWire

Steven Cohen Boosts Health Care Exposure With Theravance Biopharma Stake

Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a 7% stake in Theravance Biopharma Inc. ( TBPH , Financial) earlier this week.

1 month ago - GuruFocus

7 Busted Biotech Stocks Due for a Rebound

Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...

Other symbols:AMRNARCTARNABLUESAVA
1 month ago - InvestorPlace

Why Is Theravance Bio (TBPH) Down 36.5% Since Last Earnings Report?

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Here's Why Theravance Biopharma Stock Is Tanking Today

The company's second clinical-trial flop in as many months isn't sitting well with investors.

2 months ago - The Motley Fool

Analysts Slash Price Targets After Theravance's Failed Ulcerative Colitis Study

Analysts have lowered the price target and downgraded Theravance Biopharma Inc (NASDAQ:TBPH) after disappointing ulcerative colitis Phase 2 trial data. Related:   Theravance Stock Plunges As JAK Inhibit...

2 months ago - Benzinga

Theravance (TBPH) Suffers 2nd Study Failure in Two Months

Theravance's (TBPH) mid-stage candidate, izencitinib, fails in a study evaluating it in patients with ulcerative colitis.

2 months ago - Zacks Investment Research

Theravance Stock Plunges As JAK Inhibitor Flops Ulcerative Colitis Study

Theravance Biopharma Inc's (NASDAQ: TBPH) Izencitinib, a "gut-selective" JAK inhibitor developed for ulcerative colitis and Crohn's disease, failed a key Phase 2 trial. Johnson & Johnson's (NYSE: JNJ) p...

2 months ago - Benzinga

Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Pa...

DUBLIN and SOUTH SAN FRANCISCO, Calif., Aug. 23, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), a diversified biopharmaceutical company primari...

2 months ago - PRNewsWire

Theravance's (TBPH) Q2 Earnings Beat, Pipeline On Track

Theravance's (TBPH) loss narrows in the second quarter of 2021 while revenues decline year over year. Stock up.

2 months ago - Zacks Investment Research

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 16.67% and -14.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Recap: Theravance Biopharma Q2 Earnings

Shares of Theravance Biopharma (NASDAQ:TBPH) were flat in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 20.00% year over year to ($0.80), which be...

2 months ago - Benzinga

Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter of 2021. "We made strong ...

2 months ago - PRNewsWire

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Theravance Biopharma to Report Second Quarter 2021 Financial Results on August 3, 2021

DUBLIN, Ireland, July 20, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of...

3 months ago - PRNewsWire

Theravance Biopharma, Inc. Announces Pricing of Public Offering of Ordinary Shares

DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and comm...

4 months ago - PRNewsWire

Theravance Biopharma, Inc. Announces Proposed Public Offering of Ordinary Shares

DUBLIN, June 24, 2021 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma"), a diversified biopharmaceutical company primarily focused on the discovery, development and comm...

4 months ago - PRNewsWire

Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lu...

4 months ago - Zacks Investment Research

Theravance Biopharma Stock Drops After Nezulcitinib Disappoints In COVID-19 Study

Theravance Biopharma Inc (NASDAQ: TBPH) has announced top-line results from its Phase 2 study evaluating nezulcitinib for hospitalized patients with confirmed COVID-19 associated acute lung injury and i...

4 months ago - Benzinga